Efdir

Efmody: Effective Treatment for Congenital Adrenal Hyperplasia

Efmody is a medication specifically designed to treat congenital adrenal hyperplasia (CAH), a rare inherited condition. This condition affects the adrenal glands, which are responsible for producing hormones like cortisol and aldosterone. People with CAH often struggle to produce enough cortisol, leading to issues with hormone balance and other health problems.

Efmody contains the active substance hydrocortisone, a synthetic form of cortisol. It is formulated as modified-release capsules, which slowly release the hormone over a prolonged period, mimicking the body’s natural daily secretion of cortisol. This helps restore a more normal hormone balance and minimizes the symptoms of CAH.

Efmody is available for patients aged 12 and above. It was designated as an orphan medicine due to its use in treating a rare condition. The medication has been shown to provide adequate control of CAH in clinical studies, with some patients experiencing better control of morning hormone levels compared to standard treatments.

Efmody is only available with a prescription and should be started under the guidance of a doctor experienced in managing CAH. The benefits of Efmody have been demonstrated in a main study involving 122 patients, where it was compared to standard corticosteroid treatments. While the difference in effectiveness was not significant, the overall data suggested improved hormone balance and potential long-term control of the condition.

For safe and effective use, healthcare professionals and patients should follow the recommendations and precautions outlined in the summary of product characteristics and package leaflet. Continuous monitoring of side effects and necessary actions to protect patients are also crucial.

Efmody received a marketing authorization valid throughout the European Union on May 27, 2021. It is available in various languages, ensuring that product information can be accessed by patients and healthcare providers across the EU.